{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T18:27:53Z","timestamp":1784831273960,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,27]],"date-time":"2025-07-27T00:00:00Z","timestamp":1753574400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,27]],"date-time":"2025-07-27T00:00:00Z","timestamp":1753574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100011772","name":"Novartis Farmac\u00e9utica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011772","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018170","name":"Fondation Pierre Fabre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018170","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017655","name":"Incyte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030732","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030732","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019721","name":"Roche Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019721","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-025-04005-w","type":"journal-article","created":{"date-parts":[[2025,7,27]],"date-time":"2025-07-27T11:34:24Z","timestamp":1753616064000},"page":"320-329","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Retreatment and rechallenge with BRAF\/MEK inhibitors in patients with metastatic melanoma: results from the real-world Spanish Melanoma Registry (GEM-1801)"],"prefix":"10.1007","volume":"28","clinical-trial-number":[{"clinical-trial-number":"nct03605771","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9557-5880","authenticated-orcid":false,"given":"Pablo","family":"Ayala-de Miguel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Mu\u00f1oz-Couselo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lourdes","family":"Guti\u00e9rrez-Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Antonio","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor","family":"Navarro-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel \u00c1ngel","family":"Berciano-Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Garc\u00eda-Arroyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Aguado-de la Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Cerezuela-Fuentes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Majem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a","family":"Campos-Balea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ainara","family":"Soria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berta","family":"Hern\u00e1ndez-Mar\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almudena","family":"Garc\u00eda-Casta\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvador","family":"Mart\u00edn-Algarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2476-668X","authenticated-orcid":false,"given":"Iv\u00e1n","family":"M\u00e1rquez-Rodas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,27]]},"reference":[{"key":"4005_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2023.102515","volume":"88","author":"S Li","year":"2024","unstructured":"Li S, Tang T, Han J, Liu W, Chen R, Deng H, et al. The reduced mortality of malignant melanoma at the population level is mainly attributable to treatment advances for the past decade. Cancer Epidemiol. 2024;88: 102515.","journal-title":"Cancer Epidemiol"},{"key":"4005_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114073","volume":"204","author":"D Schadendorf","year":"2024","unstructured":"Schadendorf D, Dummer R, Flaherty KT, Robert C, Arance A, de Groot JWB, et al. COLUMBUS 7\u00a0year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E\/K-mutant melanoma. Eur J Cancer. 2024;204: 114073.","journal-title":"Eur J Cancer"},{"key":"4005_CR3","doi-asserted-by":"publisher","first-page":"5225","DOI":"10.1158\/1078-0432.CCR-21-0809","volume":"27","author":"PA Ascierto","year":"2021","unstructured":"Ascierto PA, Dr\u00e9no B, Larkin J, Ribas A, Liszkay G, Maio M, et al. 5-year outcomes with cobimetinib plus vemurafenib in BRAFV600 mutation-positive advanced melanoma: extended follow-up of the coBRIM study. Clin Cancer Res. 2021;27:5225\u201335.","journal-title":"Clin Cancer Res"},{"key":"4005_CR4","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1056\/NEJMoa1904059","volume":"381","author":"C Robert","year":"2019","unstructured":"Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019;381:626\u201336.","journal-title":"N Engl J Med"},{"key":"4005_CR5","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41467-023-44475-6","volume":"15","author":"PA Ascierto","year":"2024","unstructured":"Ascierto PA, Casula M, Bulgarelli J, Pisano M, Piccinini C, Piccin L, et al. Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial. Nat Commun. 2024;15:146.","journal-title":"Nat Commun"},{"key":"4005_CR6","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1200\/JCO.22.01763","volume":"41","author":"MB Atkins","year":"2023","unstructured":"Atkins MB, Lee SJ, Chmielowski B, Tarhini AA, Cohen GI, Truong T-G, et al. Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: the DREAMseq trial-ECOG-ACRIN EA6134. J Clin Oncol. 2023;41:186\u201397.","journal-title":"J Clin Oncol"},{"key":"4005_CR7","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nature11814","volume":"494","author":"M Das Thakur","year":"2013","unstructured":"Das Thakur M, Salangsang F, Landman AS, Sellers WR, Pryer NK, Levesque MP, et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature. 2013;494:251\u20135.","journal-title":"Nature"},{"key":"4005_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ejca.2021.11.022","volume":"162","author":"SM Goldinger","year":"2022","unstructured":"Goldinger SM, Buder-Bakhaya K, Lo SN, Forschner A, McKean M, Zimmer L, et al. Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. Eur J Cancer. 2022;162:22\u201333.","journal-title":"Eur J Cancer"},{"key":"4005_CR9","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1056\/NEJMoa2404139","volume":"391","author":"GV Long","year":"2024","unstructured":"Long GV, Hauschild A, Santinami M, Kirkwood JM, Atkinson V, Mandala M, et al. Final results for adjuvant Dabrafenib plus Trametinib in stage III melanoma. N Engl J Med. 2024;391:1709\u201320.","journal-title":"N Engl J Med"},{"key":"4005_CR10","doi-asserted-by":"publisher","unstructured":"World Medical Association. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. JAMA. 2013;310(20):2191\u20132194. https:\/\/doi.org\/10.1001\/jama.2013.281053","DOI":"10.1001\/jama.2013.281053"},{"key":"4005_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12102801","author":"I Proietti","year":"2020","unstructured":"Proietti I, Skroza N, Bernardini N, Tolino E, Balduzzi V, Marchesiello A, et al. Mechanisms of acquired BRAF inhibitor resistance in melanoma: a systematic review. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers12102801.","journal-title":"Cancers (Basel)"},{"key":"4005_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113455","volume":"196","author":"A Dayimu","year":"2024","unstructured":"Dayimu A, Gupta A, Matin RN, Nobes J, Board R, Payne M, et al. A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAFV600 mutant advanced melanoma (INTERIM). Eur J Cancer. 2024;196: 113455.","journal-title":"Eur J Cancer"},{"key":"4005_CR13","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1038\/s41591-020-1060-8","volume":"26","author":"AP Algazi","year":"2020","unstructured":"Algazi AP, Othus M, Daud AI, Lo RS, Mehnert JM, Truong T-G, et al. Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial. Nat Med. 2020;26:1564\u20138.","journal-title":"Nat Med"},{"key":"4005_CR14","doi-asserted-by":"publisher","first-page":"7008","DOI":"10.1038\/s41467-021-26572-6","volume":"12","author":"M Gonzalez-Cao","year":"2021","unstructured":"Gonzalez-Cao M, de Las M, Casas C, Oramas J, Berciano-Guerrero MA, de la Cruz L, Cerezuela P, et al. Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial. Nat Commun. 2021;12:7008.","journal-title":"Nat Commun"},{"key":"4005_CR15","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/nature13121","volume":"508","author":"C Sun","year":"2014","unstructured":"Sun C, Wang L, Huang S, Heynen GJJE, Prahallad A, Robert C, et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature. 2014;508:118\u201322.","journal-title":"Nature"},{"key":"4005_CR16","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ejca.2020.07.016","volume":"138","author":"C Gebhardt","year":"2020","unstructured":"Gebhardt C, Ascierto P, Atkinson V, Corrie P, Dummer R, Schadendorf D. The concepts of rechallenge and retreatment in melanoma: a proposal for consensus definitions. Eur J Cancer. 2020;138:68\u201376.","journal-title":"Eur J Cancer"},{"key":"4005_CR17","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1097\/CMR.0b013e3283541541","volume":"22","author":"AC Seghers","year":"2012","unstructured":"Seghers AC, Wilgenhof S, Lebb\u00e9 C, Neyns B. Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor. Melanoma Res. 2012;22:466\u201372.","journal-title":"Melanoma Res"},{"key":"4005_CR18","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1097\/CMR.0000000000000196","volume":"25","author":"J Roux","year":"2015","unstructured":"Roux J, Pages C, Malouf D, Basset Seguin N, Madjlessi N, Baccard M, et al. BRAF inhibitor rechallenge in patients with advanced BRAF V600-mutant melanoma. Melanoma Res. 2015;25:559\u201363.","journal-title":"Melanoma Res"},{"key":"4005_CR19","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1007\/s12094-018-02028-0","volume":"21","author":"D Vi\u00f1al","year":"2019","unstructured":"Vi\u00f1al D, Martinez D, Espinosa E. Efficacy of rechallenge with BRAF inhibition therapy in patients with advanced BRAFV600 mutant melanoma. Clin Transl Oncol. 2019;21:1061\u20136.","journal-title":"Clin Transl Oncol"},{"issue":"5","key":"4005_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59050975","volume":"59","author":"CS Kosmidis","year":"2023","unstructured":"Kosmidis CS, Papadopoulou K, Mystakidou CM, Papadopoulou E, Mantalovas S, Varsamis N, et al. Melanoma: BRAfi rechallenge. Medicina (Kaunas). 2023;59(5): 975.","journal-title":"Medicina (Kaunas)"},{"key":"4005_CR21","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ejca.2017.12.007","volume":"91","author":"S Valpione","year":"2018","unstructured":"Valpione S, Carlino MS, Mangana J, Mooradian MJ, McArthur G, Schadendorf D, et al. Rechallenge with BRAF-directed treatment in metastatic melanoma: a multi-institutional retrospective study. Eur J Cancer. 2018;91:116\u201324.","journal-title":"Eur J Cancer"},{"key":"4005_CR22","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1097\/CMR.0000000000000662","volume":"30","author":"B Cybulska-Stopa","year":"2020","unstructured":"Cybulska-Stopa B, Rogala P, Czarnecka AM, Galus \u0141, Dziura R, Rajczykowski M, et al. BRAF and MEK inhibitors rechallenge as effective treatment for patients with metastatic melanoma. Melanoma Res. 2020;30:465\u201371.","journal-title":"Melanoma Res"},{"key":"4005_CR23","doi-asserted-by":"publisher","first-page":"34336","DOI":"10.18632\/oncotarget.26149","volume":"9","author":"JK Tietze","year":"2018","unstructured":"Tietze JK, Forschner A, Loquai C, Mitzel-Rink H, Zimmer L, Meiss F, et al. The efficacy of re-challenge with BRAF inhibitors after previous progression to BRAF inhibitors in melanoma: a retrospective multicenter study. Oncotarget. 2018;9:34336\u201346.","journal-title":"Oncotarget"},{"key":"4005_CR24","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S1470-2045(17)30171-7","volume":"18","author":"M Schreuer","year":"2017","unstructured":"Schreuer M, Jansen Y, Planken S, Chevolet I, Seremet T, Kruse V, et al. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial. Lancet Oncol. 2017;18:464\u201372.","journal-title":"Lancet Oncol"},{"key":"4005_CR25","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1111\/jdv.14268","volume":"31","author":"VC Amann","year":"2017","unstructured":"Amann VC, Hoffmann D, Mangana J, Dummer R, Goldinger SM. Successful retreatment with combined BRAF\/MEK inhibition in metastatic BRAFV600-mutated melanoma. J Eur Acad Dermatol Venereol. 2017;31:1638\u201340.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4005_CR26","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1002\/cncr.35178","volume":"130","author":"OJ Van Not","year":"2024","unstructured":"Van Not OJ, van den Eertwegh AJM, Haanen JB, van Rijn RS, Aarts MJB, van den Berkmortel FWPJ, et al. BRAF\/MEK inhibitor rechallenge in advanced melanoma patients. Cancer. 2024;130:1673\u201383.","journal-title":"Cancer"},{"key":"4005_CR27","doi-asserted-by":"publisher","first-page":"3754","DOI":"10.3390\/cancers15153754","volume":"15","author":"JN Priantti","year":"2023","unstructured":"Priantti JN, Vilbert M, Madeira T, Moraes FCA, Hein ECK, Saeed A, et al. Efficacy and safety of rechallenge with BRAF\/MEK inhibitors in advanced melanoma patients: a systematic review and meta-analysis. Cancers (Basel). 2023;15:3754.","journal-title":"Cancers (Basel)"},{"key":"4005_CR28","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/s41416-020-01121-y","volume":"124","author":"P Bhave","year":"2021","unstructured":"Bhave P, Pallan L, Long GV, Menzies AM, Atkinson V, Cohen JV, et al. Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis. Br J Cancer. 2021;124:574\u201380.","journal-title":"Br J Cancer"},{"key":"4005_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7257","volume":"13","author":"D Dima","year":"2024","unstructured":"Dima D, Lopetegui-Lia N, Ogbue O, Osantowski B, Ullah F, Jia X, et al. Real-world outcomes of patients with resected stage III melanoma treated with adjuvant therapies. Cancer Med. 2024;13: e7257.","journal-title":"Cancer Med"},{"key":"4005_CR30","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.lungcan.2016.06.008","volume":"99","author":"F Cappuzzo","year":"2016","unstructured":"Cappuzzo F, Morabito A, Normanno N, Bidoli P, Del Conte A, Giannetta L, et al. Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer. Lung Cancer. 2016;99:31\u20137.","journal-title":"Lung Cancer"},{"key":"4005_CR31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e21196","author":"NF Uy","year":"2023","unstructured":"Uy NF, Tratt M, Eaton KD, Santana-Davila R, Baik CS. Osimertinib rechallenge in advanced EGFR non-small cell lung cancer patients. J Clin Oncol. 2023. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.e21196.","journal-title":"J Clin Oncol"},{"key":"4005_CR32","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.lungcan.2016.12.002","volume":"104","author":"GC Chang","year":"2017","unstructured":"Chang GC, Tseng CH, Hsu KH, Yu CJ, Yang CT, Chen KC, et al. Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - a multicenter retrospective SEQUENCE study. Lung Cancer. 2017;104:58\u201364.","journal-title":"Lung Cancer"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04005-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-04005-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04005-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T21:08:00Z","timestamp":1768165680000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-04005-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,27]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["4005"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-04005-w","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,27]]},"assertion":[{"value":"26 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"PAM has received honoraria for advisory role from Sanofi and Sun Pharma and speaking grants and travel\/accommodation expenses from MSD, Pierre-Fabre and Novartis. MABG has received honoraria for consulting fees, lectures, speaker bureaus, manuscript writing and educational events from BMS, MSD, Novartis, Pierre Fabre and Regeneron. CAR has received honoraria for consulting fees, lectures, speaker bureaus, manuscript writing and educational events from Takeda, MSD, Roche, Pierre Fabre, Regeneron, Astra Zeneca, Amge and Pfizer, travel\/accommodation expenses from Pierre Fabre and MSD and research funding from Astra Zeneca, BMS, Mirati, MSD and Amgen. PCF has received consulting fees from Pierre Fabre, honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events from BMS, MSD, Novartis and Pierre Fabre and travel\/accommodation expenses from MSD, Novartis and Pierre Fabre. BCB has received fees, honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events from BMS, MSD, Novartis, Pierre Fabre, Roche and Regeneron and travel\/accommodation expenses from MSD, Novartis and Pierre Fabre. IMR has received honoraria for advisory role from Amgen, Astra Zeneca, BiolineRx, BMS, Celegene, GSK, Highlight Therapeutics, Immunocore, Merck Serono, MSD, Novartis, Pierre Fabre, Regeneron, Roche, Sanofi and Sun Pharma and travel\/accommodation expenses from Amgen, BMS, GSK, Highlight Therapeutics, MSD, Novartis, Pierre Fabre, Roche and Sun Pharma. The remaining co-authors have no conflicts of interest to declare regarding this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study was approved by the Ethics investigational committee of Hospital Universitario Gregorio Mara\u00f1\u00f3n (Reference: 06\/2018).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients provided written informed consent for study participation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}